1887
Volume 2022, Issue 1
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Coronavirus disease 2019 (COVID-19) has become one of the worst global pandemics in recent history. Post-COVID-19 interstitial lung disease is a significant concern in COVID-19 survivors. It is a disabling clinical condition for patients and a burden on the healthcare system. With time and subsequent waves of COVID-19 globally, the post-COVID-19 sequelae of lung diseases can be debilitating. We report cases of three patients with persistent hypoxia post-COVID-19, raising concerns for interstitial lung disease in Qatar. In this report, we shared our experience of the patient's clinical course, complications, and outcomes with post-COVID-19 sequelae of lung parenchymal disease. Patients were followed up during and after treatment until recovery or discharge from the hospital.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2022.2
2022-02-18
2022-05-17
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2022/1/qmj.2022.2.html?itemId=/content/journals/10.5339/qmj.2022.2&mimeType=html&fmt=ahah

References

  1. Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa GD, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? The Lancet Respiratory Medicine. 2020; 8:(8):750–2.
    [Google Scholar]
  2. Cortinovis M, Perico N, Remuzzi G. Long-term follow-up of recovered patients with COVID-19. The Lancet. 2021; 397:(10270):173–5.
    [Google Scholar]
  3. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021; 397:(10270):220–32.
    [Google Scholar]
  4. Gómez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines (Basel). 2021; 9:(3):243.
    [Google Scholar]
  5. Vasarmidi E, Tsitoura E, Spandidos DA, Tzanakis N, Antoniou KM. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review).Exp Ther Med. 2020; 20:(3):2557–60.
    [Google Scholar]
  6. Wells AU, Devaraj A, Desai SR. Interstitial Lung Disease after COVID-19 Infection: A Catalog of Uncertainties.Radiology. 2021; 299:(1):E216–E8.
    [Google Scholar]
  7. Raghu G, Wilson KC. COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. The Lancet Respiratory medicine. 2020; 8:(9):839–42.
    [Google Scholar]
  8. Nabahati M, Ebrahimpour S, Khaleghnejad Tabari R, Mehraeen R. Post-COVID-19 pulmonary fibrosis and its predictive factors: a prospective study. Egyptian Journal of Radiology and Nuclear Medicine. 2021; 52:(1):248.
    [Google Scholar]
  9. Rai DK, Kumar S, Sahay N. Post-COVID-19 pulmonary fibrosis: A case series and review of literature. Journal of family medicine and primary care. 2021; 10:(5):2028–31.
    [Google Scholar]
  10. Saurabh Karmakar PS, Ameet Harishkumar, Deependra Kumar Rai. Evgenia Koutsouki HB, editor: EMJ 2020. [cited 2021]. Available from: https://www.emjreviews.com/respiratory/article/post-covid-19-pulmonary-fibrosis-report-of-two-cases/.
    [Google Scholar]
  11. Earl N, Schoeneberg D, Davidson PD. Severe progression of idiopathic pulmonary fibrosis post-COVID-19 infection. BMJ Case Rep. 2021; 14:(10):e244472.
    [Google Scholar]
  12. Scelfo C, Fontana M, Casalini E, Menzella F, Piro R, Zerbini A, et al. A Dangerous Consequence of the Recent Pandemic: Early Lung Fibrosis Following COVID-19 Pneumonia - Case Reports. Therapeutics and clinical risk management. 2020;16:1039–46.
    [Google Scholar]
  13. Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulmonary medicine. 2020;2020:6175964.
    [Google Scholar]
  14. Generali D, Bosio G, Malberti F, Cuzzoli A, Testa S, Romanini L, et al. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2021;104:433–40.
    [Google Scholar]
  15. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet Respiratory medicine. 2020; 8:(8):807–15.
    [Google Scholar]
  16. Gordon AC, Mouncey PR. Interleukin-6 ReceptorAntagonists in Critically Ill Patients with Covid-19. 2021; 384:(16):1491–502.
    [Google Scholar]
  17. Ogata H, Nakagawa T, Sakoda S, Ishimatsu A, Taguchi K, Kadowaki M, et al. Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019. Respirology Case Reports. 2021; 9:(5):e00744.
    [Google Scholar]
  18. Grigoletto I, Cavalheri V, Lima FF, Ramos EMC. Recovery after COVID-19: The potential role of pulmonary rehabilitation. Brazilian journal of physical therapy. 2020; 24:(6):463–4.
    [Google Scholar]
  19. Funke-Chambour M, Bridevaux P-O, Clarenbach CF, Soccal PM, Nicod LP, von Garnier C, et al. Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID. Respiration. 2021; 100:(8):826–41.
    [Google Scholar]
  20. Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung Fibrosis after COVID-19: Treatment Prospects. Pharmaceuticals (Basel). 2021; 14:(8):807.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2022.2
Loading
/content/journals/10.5339/qmj.2022.2
Loading

Data & Media loading...

  • Article Type: Case Report
Keyword(s): COVID-19critical carelung parenchymal diseases and Medicine
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error